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Dengue virus type 2 and Yellow fever virus are arthropod-borne flaviviruses causing hemorrhagic fever in humans.
Identification of virus receptors is important in understanding flavivirus pathogenesis. The aim of this work was to study the
role of cellular heparan sulfate in the adsorption of infectious Yellow fever and Dengue type 2 viruses. Virus attachment was
assessed by adsorbing virus to cells, washing unbound virus away, releasing cell-bound virus by freezing/thawing, and then
titrating the released infectious virus. Treatment of cells by heparin-lyase, desulfation of cellular heparan sulfate, or treatment
of the virus with heparin inhibited cell binding of both viruses. Heparin also inhibited Yellow fever virus infection by 97%. Using
infectious virus, the present work shows the importance of heparan sulfate in binding and infection of these two flaviviruses.
© 2002 Elsevier Science
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Dengue (DEN) viruses and Yellow fever (YF) virus are
arthropod-borne flaviviruses that cause hemorrhagic fe-
ver (associated with hepatitis) in humans (Henchal et al.,
1990; Monath and Heinz, 1996). These viruses belong to
the family of the Flaviviridae, which also includes hepa-
titis C virus (HCV, genus Hepacivirus). The genomes of
YF virus and DEN viruses are single-stranded, positive-
sense RNA molecules coding for the structural proteins
(core, membrane (M), and envelope (E)) in the 59 quarter
of the genome and for eight nonstructural proteins in the
remainder of the coding sequence (Rice et al., 1985).
Mosquito-borne YF and DEN viruses are responsible for
an important public health problem caused, among other
things, by the failure to maintain programs for controlling
the mosquito vector, Aedes aegyptii. YF diseases are
increasing and some 208 cases occurred in 1999, prin-
cipally in South America, with a 49% of mortality rate
(WHO Weekly Epidemiologic Record, 2000). Although the
virus can be controlled by the use of an efficient live
vaccine, serious adverse side effects were recently re-
ported by Marianneau et al. (2001). In contrast, DEN
viruses are endemic in (sub)tropical areas and affect one
million individuals each year, with a high mortality rate in
children (Monath and Heinz, 1996). Furthermore, one
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162outbreak of Dengue occurred in the United States in 1995
(CDC Weekly Report, 1996). There is no specific treat-
ment for flavivirus infections.
The binding of a virus to its specific receptor(s) is a
major factor of cellular tropism and a critical determinant
of pathogenesis. Although some work has been carried
out on DEN virus binding (Ramos-Castaneda et al., 1997;
Munoz et al., 1998; Bielefeldt-Ohmann, 1998; Hung et al.,
1999), the initial event of flavivirus infection has not been
described in detail and little is known about the molec-
ular basis of the binding of flaviviruses to their target
cells. Heparan sulfate (HS) (the most ubiquitous member
of molecules of the glycosaminoglycan (GAG) family) is
used by many viruses to bind to target cells, such as
herpes simplex virus (Shukla et al., 1999), human immu-
nodeficiency virus (Patel et al., 1993), foot and mouth
disease virus (Fry et al., 1999), vaccinia virus (Lin et al.,
2000), adenoassociated virus 2 (Summerford and Sam-
ulski, 1998), Sindbis virus (Byrnes and Griffin, 1998; Klim-
stra et al., 1999), papillomavirus (Joyce et al., 1999), re-
spiratory syncytial virus (Feldman et al., 2000; Hallak et
al., 2000), adenovirus types 2 and 5 (Dechecchi et al.,
2001), and Echovirus (Goodfellow et al., 2001). HS could
act directly as a receptor or help to concentrate these
viruses on the cell surface to facilitate the interaction
with specific high-affinity receptors. Recently, Chen et al.
(1996, 1997) showed that a soluble, recombinant and
hybrid surface glycoprotein of DEN-2 virus bound to
highly sulfated GAGs on the surface of Vero cells and
163DENGUE AND YELLOW FEVER BINDING TO HEPARAN SULFATEthat infection of these cells could be prevented by hep-
arin and by high-sulfate HS.
Instead of the binding of recombinant proteins to cells,
the present work studies the role of HS in binding of
infectious DEN-2 viruses to the surface of CHO and Vero
cells. It also shows for the first time that YF virus also
binds to HS on the surface of Vero cells and that this is
a prerequisite for infection. Heparin can inhibit YF virus
infection of Vero cells by up to 97%.
RESULTS
Development of a virus binding assay
For the validation of the binding assay, three virus
dilutions (undiluted and 3 times and 10 times diluted)
were used to inoculate two sets of Vero cells. The undi-
luted inoculum contained 104.6 50% tissue culture infec-
tious doses per well (TCID50/well) for DEN-2 virus and
104.9 TCID50/well for YF virus (Table 1). After 15 min the
cells were washed to remove unbound virus. Then one
set (called binding set) was immediately collected and
the infectious virus that was bound to the cells was
released by freezing/thawing and titrated. Less than 1%
of infectivity remained associated with the pellet of the
cell debris. The other set (called replicating set) was
incubated with medium for 48 h (DEN-2 virus) or 36 h (YF
virus) before freezing/thawing and titration of released
virus. The results shown in Table 1 indicate that the titers
of virus released from the cells of the binding set and the
replicating set were proportional to the dilution factors of
the inoculum, although the titers for the replicating set
were about 1000 times higher than those for the binding
set. A Spearman’s test demonstrated the correlation be-
tween the results obtained with the two sets of cells
TABLE 1
Development of a Virus-Binding Assay
Virus
Inoculum
dilution
TCID50/well
(31023)
binding set
TCID50/well
(31026)
replicating set
DEN-2 virus Undiluted 7.1 6 0.6 4.6 6 0.2
Diluted 3 times 2.0 6 0.2 1.6 6 0.3
Diluted 10 times 0.36 6 0.03 0.34 6 0.07
YF virus Undiluted 8.9 6 1.2 15.4 6 2.3
Diluted 3 times 2.0 6 0.2 6.8 6 1.2
Diluted 10 times 0.7 6 0.1 1.1 6 0.2
Note. The binding assay (see Materials and Methods) was per-
formed with different virus dilutions (1, 1/3, 1/10). For the binding set,
cells were collected after 15 min. For the replicating set, cells were
cultured for 48 h (DEN-2 virus) or for 36 h (YF virus) before collection
and virus titration. The undiluted inoculum contained 104.6 TCID50/well
for DEN-2 virus and 104.9 TCID50/well for YF virus.(Rho . 0.9, P , 0.01). We will subsequently use the
assay described as the binding set to study the effects ofGAG modifications on the binding of DEN and YF vi-
ruses.
DEN-2 virus and YF virus bind to specific, sulfated
GAG species on the surface of cells
GAG-lyases remove GAGs from cells. Attachment of a
DEN-2 recombinant E glycoprotein to Vero cells was
reduced when GAGs were enzymatically removed (Chen
et al., 1997). To demonstrate that GAGs play a role in the
binding of infectious DEN-2 and YF viruses to the target–
cell surface, Vero cells were treated for 1 h at 37°C with
heparin-lyase I (specific for highly sulfated domains of
HS and heparin) and chondroitin ABC-lyase (specific for
chondroitin and dermatan sulfate). Heparin-lyase I sig-
nificantly inhibited binding of both flaviviruses (Fig. 1A)
but chondroitin ABC-lyase had no effect. This enzyme
specificity implies that the viruses bind specifically to HS.
For most of the heparin-binding viruses, sulfation of
the cell surface is critical for virus binding and infection.
Addition of sodium chlorate to sulfate-free medium
blocks cellular ATP-sulfurylase and sulfate adenyl trans-
ferase activities and reduces incorporation of sulfate into
GAGs (Baeuerle and Hunter, 1986). Cells grown in this
type of medium had a severely reduced capacity to bind
DEN-2 and YF viruses (less than 20% of the untreated
control) (Fig. 1B). As a control, cells treated as described
above were supplemented with sodium sulfate, which
reversed the effect of the sodium chlorate and led to
partial restoration of virus binding.
Binding of DEN-2 virus to Chinese hamster ovary
(CHO) cells defective in GAG expression
If cell surface GAGs are involved in flavivirus adsorp-
tion, cell lines deficient in enzymes needed to produce
the various GAGs might differ in their susceptibility to
bind flaviviruses. Mutant cell lines derived from CHO K1
are psgB-618, which is defective for galactosyltrans-
ferase-I, resulting in the inhibition of both chondroitin and
HS synthesis, and psgD-677, which is defective for HS
polymerization and expression, but has an increased
expression of other GAGs (Esko et al., 1985, 1987; Lidholt
et al., 1992). DEN-2 virus binding to the two mutant cell
lines was reduced by more than 75% compared to bind-
ing to wild-type CHO K1, with no significant difference
between the two mutants (Fig. 2). YF virus adsorption to
CHO cells was too low to be studied.
Heparin inhibits Vero cell binding by DEN-2 and YF
viruses
If the presence of HS on the cell surface influences
flavivirus binding, then soluble HS might also interfere
with virus adsorption. Heparin has the same carbohy-
drate composition as HS except that it contains more
iduronic acid (the epimerized form of glucuronic acid), is
more highly sulfated, and is less acetylated (Lindahl et
164 GERMI ET AL.al., 1989; Lindahl, 1990). Heparin is often used experi-
mentally as an HS analog. After incubation with increas-
ing concentrations of heparin for 1 h at 37°C, attachment
of DEN-2 (Fig. 3A) and YF (Fig. 3B) viruses was reduced
in a dose-dependent manner. Maximum inhibition was
between 60 and 70% and the 50% inhibitory dose (ID50)
FIG. 1. Effect of GAG-lyase treatment and GAG desulfation on DEN-2
and YF virus adsorption to cells. (A) Binding of DEN-2 (open bars) and
YF (shaded bars) virus to Vero cells after treatment of the cells with
heparin-lyase I or chondroitin ABC-lyase. The DEN-2 virus titer of the
untreated control was 103.2 TCID50/well and the YF virus titer of the
untreated control was 103.2 TCID50/well. (B) Binding of virus to Vero cells
in the presence of the sulfation inhibitor sodium chlorate, with or
without sodium sulfate which restored sulfation. Sulfated and nonsul-
fated cells were inoculated with DEN-2 (open bars) or YF (shaded bars)
viral suspensions for the binding assay. The DEN-2 untreated control
was 103.1 TCID50/well and the YF untreated control was 10
3.3 TCID50/
well. Titers were calculated in TCID50/well and results are presented in
percentage of untreated control. The mean values and the standard
deviations correspond to a quadruplicate assay. This experiment was
repeated two times (GAG-lyases) or three times (desulfation) with
similar results. *Student’s t test for the difference between cells treated
with heparin-lyase and nontreated cells or cells treated with sodium
chlorate and untreated cells, P , 0.05. ¤Student’s t test for the differ-
ence between cells treated with heparin-lyase I and chondroitin-lyase
or cells treated by sodium chlorate or with sodium chlorate and sulfate,
P , 0.05.was around 0.2 mg/mL for both viruses. The effect of
exogenous chondroitin sulfate B on cell attachment wasalso determined to assess the specificity of the heparin–
virus interaction. In agreement with the result shown in
Fig. 1A, 200 mg/mL chondroitin sulfate B (corresponding
to the highest dose of heparin) did not inhibit binding of
either of the viruses (data not shown).
Heparin inhibits infection of Vero cells by YF virus
Chen et al. (1997) have shown that DEN-2 virus infec-
tion was inhibited by heparin and high-sulfate HS (max-
imum inhibitions of 99 and 87%, respectively). Therefore,
in a final experiment, we tested the inhibition of infection
of YF virus by heparin. Figure 4 shows that soluble
heparin indeed reduced the production of infectious YF
virus from 106.3 to 104.7 TCID50/well (97% inhibition) with
an ID50 of about 0.2 mg/mL.
DISCUSSION
HS is important for cell adsorption of recombinant
DEN-2 virus E glycoprotein and for virus infection (Chen
et al., 1997). In the present work we have directly quan-
tified the binding of infectious DEN-2 and YF virus to Vero
cells. We have shown that binding of both flaviviruses to
cells was strongly and specifically reduced when HS
was desulfated or enzymatically removed from the cell
surface. Moreover, heparin but not chondroitin sulfate
reduced virus binding. Heparin was also able to inhibit
the infection process of YF virus as was shown before for
DEN-2 virus (Chen et al., 1997; Hung et al., 1999). These
two groups have determined the ID50 of heparin for DEN
virus infection and for binding of recombinant DEN gly-
coprotein to cells. These ID50 values were similar to the
FIG. 2. DEN-2 virus binding to wild-type and mutant CHO cells.
Binding of DEN-2 virus to wild-type CHO cells and two defective
mutants lacking both heparan and chondroitin sulfate (CHO pgsB-618
defective in galactosyltransferase I) or lacking heparan sulfate only
(CHO psgD-677 defective in heparan sulfate polymerization). Titers
were calculated in TCID50/mL and results are presented as percent-
ages of the untreated control. The DEN-2 untreated control was 102.4
TCID50/well. The mean values and the standard deviations represent
four independent assays. *Student’s t test for the difference between
wild-type CHO cells and defective mutant CHO cells, P , 0.05.
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DEN and YF viruses and for the infection by YF virus. The
binding of YF virus to wild-type CHO K1 cells was too low
to be detected. Moreover, DEN-2 virus binding to these
cells was 80% lower than on Vero cells (results not
shown). Chen et al. (1996) have shown that the recom-
binant envelope protein of DEN-2 virus binds three times
more efficiently to Vero cells than to CHO cells. This
could be due to a difference in the nature or density of
HS on the surface of the two cell types or to a difference
in secondary receptor types on the cells.
Apart from indirect entry into cells of DEN and YF
viruses by the antibody-Fc receptor (Schlesinger and
Brandriss, 1983; Brandt et al., 1982; Wang et al., 1995),
several virus receptors have been described for YF and
DEN-2 viruses. The French neurotropic strain of YF rec-
ognizes different receptors in mouse and monkey brains
(Ni et al., 2000). DEN-2 virus was found to bind to 80- and
67-kDa proteins on the membrane of an Aedes albopic-
tus derived cell line C6/36 (Munoz et al., 1998) to a
FIG. 3. Effect of heparin on DEN-2 and YF virus binding to Vero cells.
DEN-2 virus (A) or YF virus (B) suspension was treated with differing
heparin concentrations before the binding assay was performed. Re-
sults are presented as percentages of untreated control 6 standard
deviation. The mean values shown correspond to a quadruplicate
assay. This experiment was repeated two times with similar results.65-kDa protein on mouse neuroblastoma cells (Ramos-
Castaneda et al., 1997) and to a 100-kDa protein inhuman bone marrow (Rothwell et al., 1996). The differ-
ences in the binding affinity and the cell surface density
of these proteins could account for the viral tropism
observed (Putnak et al., 1997).
The interaction between viruses and GAGs seems to
be complex and to depend on numerous factors. A study
of HS as receptor for classical swine fever virus sug-
gested that the interaction between GAGs and virus is
dependent on the virus strain, the target cell, and the
number of passages of the virus in cell culture. The
binding of the virus to GAGs could be specific but could
also be due to nonspecific electrostatic interactions.
Results obtained in vitro, ex vivo, and in vivo are also
different (Hulst et al., 2000). Thus it would be important to
perform ex vivo and in vivo studies on the interaction
between HS and flaviviruses. Recently, a new animal
model for flavivirus infection was established using the
murine Modoc virus (Leyssen et al., 2001). This system
may provide information on the flavivirus infection pro-
cess in general.
Our results with infectious DEN-2 and YF viruses show
that the interactions between these viruses and cell
surface GAGs are important for virus–cell attachment.
HS may be required to concentrate virus particles at the
cell surface and to facilitate binding to a second receptor
specifically recognized by the viral envelope protein.
Alternatively, HS may initiate changes in the envelope of
the adsorbed virus particles that trigger the process of
fusion with the cellular membrane. Other Flaviviridae
may use the same mechanism to bind to target cells.
Two potential GAG-binding motifs were determined on
the E protein of Murray Valley encephalitis virus (genus
Flavivirus) (Chen et al., 1997), but other surface mole-
cules are also used as receptors (Lee and Lobigs, 2000).
Bovine viral diarrhea virus (BVDV, Pestivirus genus) binds
also to HS but additionally a 50-kDa protein has been
FIG. 4. Effect of heparin on YF virus replication. Cells were incubated
for 48 h with YF virus in the presence of various heparin concentrations,
washed, frozen, and thawed before virus titer determination. The mean
values of the virus titers correspond to a quadruplicate assay.
166 GERMI ET AL.identified as a putative BVDV receptor (Zheng et al., 1998;
Iqbal et al., 2000). The HCV E2 envelope glycoprotein
seems to interact with GAGs (Meyer et al., 2000;
Takikawa et al., 2000) but this virus may have multiple
receptors (Germi et al., 2001). Therefore, infection by
HCV may have similar features as infection by DEN and
YF viruses.
MATERIALS AND METHODS
Cell culture
The following adherent cell lines were used: African
green monkey kidney Vero cell line (ATCC CCL-81); wild-
type Chinese hamster ovary cells (CHO K1); and mutant
CHO cells, CHO psgB-618 ATCC CRL 2241 (defective in
galactosyltransferase I) and CHO psgD-677 ATCC CRL
2244 (defective in HS polymerization). Vero cells were
grown in M199 medium and CHO cells in F12K Ham’s
medium supplemented with 10% heat-inactivated fetal
calf serum (FCS) at 37°C with 5% CO2. All media and FCS
were from Life Technologies SARL, Cergy Pontoise,
France.
For all the experiments described below (GAG-lyases,
chlorate 6 sulfate, heparin) the viability of the cells was
tested by trypan blue staining. Cell viability was not
affected significantly by any of the treatments (Student’s
t test: P . 0.05).
Viruses
Dengue virus type 2 strain New Guinea C and Yellow
fever virus strain 17D viruses were propagated in Vero
cells grown in M199 FCS-free medium. The culture su-
pernatants were collected, centrifuged to eliminate re-
maining cells, aliquoted, and frozen at 280°C.
DEN-2 virus and YF 17D virus binding and infectivity
assays
Cells were distributed to 24-well plates and grown to
confluence (one million cells per well). The cells were
then washed twice with FCS-free medium and incubated
for 15 min at 4°C with DEN-2 virus (104.6 TCID50/well) or
YF virus (104.9 TCID50/well). Unbound virus was removed
by washing each well three times with culture medium.
Then the cells, in 1 mL of medium, were frozen at 280°C
and thawed at 37°C three times to release bound virus.
Four hundred microliters (8 3 50 mL) of the clarified virus
suspension was used for virus titration on Vero cells
(96-well plates). The virus titer was determined using the
method described by Reed and Muench (1938). For each
experiment, four independent assays were performed.
When the binding assay was carried out on CHO cells,
the infectious titer was established using Vero cells be-
cause of the lack of cytopathic effect of DEN-2 virus on
CHO cells. As a control, virus that remained associated
with the cell debris after freezing/thawing was titratedafter mixing the membrane pellet with 400 mL of medium.
Less than 14 TCID50/well, which represents less than 1%
of the virus released by freezing and thawing after the
binding assay, remained associated with the cell debris.
GAG-lyase treatment
Before the binding assay, confluent Vero cells were
washed and incubated 1 h at 37°C with 300 mL of lyase
buffer (10 mM phosphate buffer, pH 7.4, 0.14 M NaCl, 3
mM KCl, 0.5 mM MgCl2, 1 mM CaCl2, 0.1% glucose, 0.5%
bovine serum albumin (Sigma, St. Quentin-Fallavier,
France), 1% FCS) containing 0.2 IU/mL of chondroitin
ABC lyase (Sigma) or 8 mIU/mL of heparin-lyase I
(Sigma). Cells were washed with cold FCS-free medium
before inoculation with virus.
Inhibition of sulfation
Before the binding assay, Vero cells were grown to
confluence, washed with sulfate-free MEM Dulbecco’s
medium (Life Technologies SARL), and maintained 48 h
in the same medium supplemented with 10% of dialyzed
FCS in the presence of 30 mM of the sulfation inhibitor
sodium chlorate (NaClO3, Sigma). Cells were removed
from their culture surface, distributed to 24-well plates,
and grown to confluence (48 h in the same sulfate-free
medium supplemented with sodium chlorate). For the
reversal of sulfation inhibition, chlorate-treated cells
were supplemented with 10 mM sodium sulfate (Na2SO4,
Sigma).
Heparin and chondroitin sulfate interaction
with DEN-2 and YF viruses
DEN-2 virus (104.6 TCID50/well) or YF virus (10
4.9 TCID50/
well) was incubated for 1 h at 37°C with varying concen-
trations of heparin (0–0.2–2-20–200 mg/mL) or with 200
mg/mL of chondroitin sulfate B (Sigma). For the virus-
binding study, the heparin- or chondroitin sulfate
B-treated virus suspensions were used as described in
the binding assay.
For the YF virus infectivity study, the heparin-treated
virus suspensions (103.6 TCID50/well) were incubated with
the cells for 48 h. Then cells were washed three times to
eliminate heparin. The cells with 1 mL of medium were
frozen at 280°C and thawed at 37°C three times to
release viruses. The virus yield was titrated by Reed and
Muench method.
Statistical evaluation
All results are expressed as means 6 standard devi-
ations. The error bars in the graphs represent standard
deviations. Results were tested for significance using
Student’s t test and the Spearman test (Statistica kernel
version 5.5, Statsoft, Maisons-Alfort, France). Results that
had P values , 0.05 were considered significant.
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